Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26940474 | 1.00 | CA2 (0.48) | CA2MAPK1ACE2GPR84CA1 | |
| SCHEMBL27670297 | 0.92 | GPR84 (0.53) | CA2ACE2GPR84CA1FFAR1 | |
| SCHEMBL29165517 | 0.92 | GPR84 (0.53) | CA2ACE2GPR84CA1FFAR1 | |
| SCHEMBL27525393 | 0.90 | GPR84 (0.52) | CA2ACE2GPR84CA1FFAR1 | |
| SCHEMBL27523512 | 0.90 | GPR84 (0.52) | CA2ACE2GPR84CA1FFAR1 | |
| SCHEMBL27497981 | 0.90 | GPR84 (0.52) | CA2ACE2GPR84CA1FFAR1 | |
| SCHEMBL27335805 | 0.90 | GPR84 (0.52) | CA2ACE2GPR84CA1FFAR1 | |
| SCHEMBL2573721 | 0.89 | CA2 (0.54) | CA2MAPK1ACE2GPR84CA1 | |
| SCHEMBL2232093 | 0.86 | CHRM1 (0.48) | CA2MAPK1ACE2GPR84SLC1A3 | |
| SCHEMBL26940421 | 0.86 | CHRM1 (0.48) | CA2MAPK1ACE2GPR84SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127733-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210275469-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2021-09-09 | — | — | US | disclosed |
| US-11007157-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10588874-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190247334-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEXA THERAPEUTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| EP-2348833-A2 | LIQUID AQUEOUS CROP PROTECTION FORMULATIONS | BASF SE (DE) | 2011-08-03 | — | — | EP | disclosed |
| CN-1950459-B | Curable composition improved in solidification and adhesiveness | KANEGAFUCHI CHEMICAL IND | 2011-05-25 | — | — | CN | disclosed |
| WO-2010040834-A2 | LIQUID AQUEOUS CROP PROTECTION FORMULATIONS | BASF SE (DE) | 2010-04-15 | — | — | WO | disclosed |
| CN-1950459-A | Curable composition improved in solidification and adhesiveness | KANEGAFUCHI CHEMICAL IND (JP) | 2007-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275469-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | CA2 2456/4885MAPK1 4021/4885ACE2 390/4885 |
| US-20190247334-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | CA2 2456/4885MAPK1 4021/4885ACE2 390/4885 |
| US-11007157-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | CA2 2456/4885MAPK1 4021/4885ACE2 390/4885 |
| US-10588874-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | CA2 2456/4885MAPK1 4021/4885ACE2 390/4885 |
| US-20250127733-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | CA2 2456/4885MAPK1 4021/4885ACE2 390/4885 |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | CA2 2456/4885MAPK1 4021/4885ACE2 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.